Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy

Table 5 Univariate analysis between clinical characteristics and pCR in Cohort2

Patient characteristic		All patients				χ2	P
		pCR(n = 144)		NpCR(n = 735)
		N	%	N	%
Age	≤ 40	30	20.8	130	17.7	0.801	0.371
	> 40	114	79.2	605	82.3
Surgical methods	BCS	4	27.8	32	4.4	0.761	0.383
	M	140	72.2	703	95.6
Menstruatio	Yes	72	50.0	387	52.7	0.340	0.560
	No	72	50.0	348	47.3
BMI	≤ 18.5	1	0.6	18	2.4	3.488	0.322
	18.5–24	73	50.7	325	44.2
	24–30	61	42.4	348	47.3
	≥ 30	9	6.3	44	6.1
Clinical T stage	1	31	21.5	76	10.3	18.043	< 0.001
	2	101	70.1	536	73.0
	3	12	8.4	123	16.7
Clinical N stage	0	26	18.1	84	11.4	5.099	0.165
	1	79	54.9	420	57.1
	2	14	9.7	86	11.7
	3	25	17.3	145	19.8
ER	Positive	50	34.7	434	59.0	28.795	< 0.001
	Negative	94	65.3	301	41.0
PR	Positive	32	22.2	350	47.6	31.607	< 0.001
	Negative	112	77.8	385	52.4
HER-2	Positive	84	58.3	250	34.0	31.139	< 0.001
	Negative	60	41.7	485	64.0
KI67	≤ 15	32	22.2	267	36.3	10.672	< 0.001
	> 15	112	77.8	468	63.7
HR status	ER + /PR +	31	21.5	340	46.3	35.105	< 0.001
	ER + /PR-	19	13.2	94	12.8
	ER-/PR +	1	0.7	10	1.4
	ER-/PR-	93	64.6	291	39.5
P53	0	66	45.8	395	53.8	6.215	0.102
	1	34	23.6	175	23.8
	2	17	11.8	79	10.7
	3	27	19.8	86	11.7
Histological type	IDC	0	0	583	79.3	418.91	< 0.001
	ILC	0	0	21	2.9
	DCIS	30	20.8	3	0.4
	Others	114	79.2	128	17.4
Histological grade	0–1	144	100	183	12.5	290.70	< 0.001
	2	0	0	451	61.4
	3	0	0	101	26.1
Stage	I	0	0	13	1.8	10.105	0.006
	II	103	71.5	429	58.4
	III	41	28.5	293	39.8

Abbreviation: pCR Pathologic complete response, NpCR Non-pathologic complete response, HR Hormone receptor, ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor 2, IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, DCIS Ductal carcinoma in situ, BCS Breast conserving surgery, M Mastectomy. Bold values indicate that they are statistically significant at P ≤ 0.05

ISSN: 1746-1596